A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model

Journal of Asthma and Allergy

Volumn , Issue 6, 2013, Pages 43-52

  Ackerman, Stacey ^a   D'Ambrosio, Francis ^b   Greiner, Jack V ^c   Villanueva, Linda ^d   Ciolino, Joseph B ^e   Hollander, David A ^d  

^a Will's Eye Philadelphia   (United States)

^b Professional Building   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ALLERGAN INC   (United States)

^e MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Alcaftadine 0.25 ; Conjunctival allergen challenge model; Olopatadine 0.2

Indexed keywords

ALCAFTADINE; LASTACFT; OLOPATADINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CHEMOSIS; CONJUNCTIVA DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIPHORA; EYE REDNESS; EYE SWELLING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84876146919     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S38671     Document Type: Article

References (21)

1. Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc. 2007;28(4):393-397.
2. Collum LM, Kilmartin DJ. Acute allergic conjunctivitis. In: Abelson MB, editor. Allergic Diseases of the Eye. Philadelphia, PA: WB Saunders; 2000.
3. Abelson MB, Schaefer K. Functional anatomy of the human conjunctiva and cornea. In: Abelson MB, editors. Allergic Diseases of the Eye. Philadelphia, PA: WB Saunders; 2000.
4. Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011; 11(3):205-211.
5. Hughes JL, Lackie PM, Wilson SJ, Church MK, McGill JI. Reduced structural proteins in the conjunctival epithelium in allergic eye disease. Allergy. 2006;61(11):1268-1274.
6. No authors. Drugs for allergic disorders. Treat Guidel Med Lett. 2010;8(90):9-18.
7. Manzouri B, Flynn TH, Larkin F, Ono SJ, Wyse R. Pharmacotherapy of allergic eye disease. Expert Opin Pharmacother. 2006;7(9): 1191-1200.
8. Pataday® (olopatadine hydrochloride ophthalmic solution) 0.2%. [package insert]. Fort Worth, TX: Alcon Laboratories Inc; 1996.
9. Lastacaft® (alcaftadine ophthalmic solution) 0.25%. [package insert]. Irvine, CA: Allergan Inc; 2010.
10. Abelson MB, Gomes PJ. Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. Expert Opin Drug Metab Toxicol. 2008;4(4):453-461.
11. Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27(3):623-631.
12. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108(1):84-88.
13. Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR.; the Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009;31(9):1908-1921.
14. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998;81(3):211-218.
15. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998;125(6):797-804.
16. Abelson MB, Chapin MJ, Kapik BM, Shams NB. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol. 2003;121(5): 626-630.
17. Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004;26(1):35-47.
18. Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res. 2007;32(12):1017-1022.
19. Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol. 2011;5:87-93.
20. Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther. 2011;5: 77-84.
21. Contreras-Ruiz L, Schulze U, García-Posadas L, et al. Structural and functional alteration of corneal epithelial barrier under inflammatory conditions. Curr Eye Res. 2012;37(11):971-981.